Skip to content
MARKETS / XTXXF
PHARMACEUTICAL PREPARATIONS · SMALL CAP

Adastra Holdings Ltd. XTXXF

3 fiscal years on record · CAD · FY2022 reported · SEC filings only
CAD 13.3M
▲ 136.2% YoY
CAD -4.3M
CAD 694,074
Growth
CAD 13.3M
Revenue, FY2022 · full 3-year series below
Revenue CAD M Net income CAD M
FY2022 · Revenue 13.3 · Net income -4.3
5M10M-4M202020212022
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−32 cents
lost on every revenue dollar
Operating margin Net margin
FY2022 · Operating -6.0% · Net -32.2%
-100%-200%-300%202020212022
ROE

Not available in our data for this period.

Cash & shareholders
returned in FY2022 · dividends + net buybacks
Free cash flow CAD M
FY2022 · FCF 0.7
0.25M0.50M-2.00M-4.00M202020212022

Not available: we don't have the cash figure for this period.

The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · CAD
row low → row highnegative
Metric 202220212020
Revenue CAD B0.00.00.0
Operating income CAD B−0.0−0.0−0.0
EBITDA CAD B−0.0−0.0−0.0
Income tax CAD B−0.0−0.00.0
Net income CAD B−0.0−0.0−0.0
Free cash flow CAD B0.0−0.0−0.0
EPS, diluted CAD −0.07−0.05−0.19
Dividend / sh CAD ···
Payout %···
ROE %···
Shares out B0.060.07·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 0 failures in 15 reconciliationsAUDITED

Reconciled in 3 of 19 fiscal years. 80 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onnot stated in the filings
Incorporated inoutside the United States — SEC code A1
Fiscal year endsDecember 31
Data on record since2020

Share this section

Download image